Lassa-VSV targets and kills glioma, and is not neurotoxic
Lassa-VSV 靶向并杀死神经胶质瘤,并且不具有神经毒性
基本信息
- 批准号:8888841
- 负责人:
- 金额:$ 35.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-04-01 至 2020-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdoptive TransferAdverse effectsAnimal ModelAnimalsAntibodiesAttenuatedBindingBrainBrain NeoplasmsCD8B1 geneCell TransplantsCellsCessation of lifeClinical TrialsCodeComplementCoupledDataDerivation procedureDiagnosisEbola virusElectron MicroscopyFrankfurt-Marburg Syndrome VirusG Protein GeneGenesGlioblastomaGliomaGlycoproteinsGreen Fluorescent ProteinsHumanImageImmuneImmune TargetingImmune responseImmune systemImmunocompetentImmunodeficient MouseImplantIn VitroInfectionInjection of therapeutic agentInjuryIntravenousLassa virusLeadLifeLymphocytic ChoriomeningitisMalignant neoplasm of brainMalignant neoplasm of lungMediatingMicroscopeMusNeurogliaNeurologicNeuronsNormal CellOncolyticPathway interactionsPatientsPhasePlayPrimatesProteinsQuality of lifeQuantitative Reverse Transcriptase PCRRabiesRattusRecombinantsRecruitment ActivityRecurrenceReporterReporter GenesReverse Transcriptase Polymerase Chain ReactionRodentRoleSCID MiceSafetySliceSymptomsT-LymphocyteTestingTimeToxic effectTransplantationVariantVesicular stomatitis Indiana virusVirusVirus DiseasesVirus ReceptorsWorkcancer cellglioma cell lineimmunocytochemistryimplantationin vivokillingsmelanomaneoplastic cellneurotoxicneurotoxicitynoveloutcome forecastpreventpublic health relevancereceptorresearch studytumorvesicular stomatitis virus G proteinvirus development
项目摘要
DESCRIPTION (provided by applicant): Glioblastomas are aggressive and invasive brain tumors that generally lead to death within a year of diagnosis. No cure is available. Current treatments prolong life by only a few months, often at the expense of quality of life. Here we test the general hypothesis that a novel recombinant chimeric virus will target and kill gliomas with no detectable adverse effect to the brain. Of the large number of viruses we have tested, vesicular stomatitis virus (VSV) appears to be one of the most effective for targeting and destroying brain tumors. However, VSV has the potential unwanted side effect of infecting neurons, and half of our efforts in the last few years have focused on reducing or controlling potential neurotoxicity of VSV. To avoid complications and toxicity of the VSV G-protein, particularly its binding to neurons, we have compared a number of recombinant chimeric viruses in which the VSV G-protein gene was replaced by genes coding for binding glycoproteins of non-related viruses including rabies, lymphocytic choriomeningitis, Marburg, Ebola, and Lassa viruses. Of these chimeric viruses tested, one stood out as a clear superlative safe oncolytic candidate: a chimeric virus consisting of a gene coding for the Lassa glycoprotein together with genes coding for the VSV N,P,M, and L proteins, and a GFP reporter gene which further attenuates the virus. Lassa-VSV is safe, both in rodents and primates. Of considerable importance, our direct injection of Lassa-VSV into the brains of normal mice or rats, or even into the brains of immunodeficient mice has not resulted in any detectable adverse effects, whereas injections of native or other attenuated VSVs generated neurological complications sometimes resulting in death. Equally important, in our preliminary experiments in vitro and in vivo, Lassa-VSV targets and destroys gliomas completely without damage to the host brain, and extends survival of tumor-bearing mice indefinitely. In the first set of experiments, we test the hypothess that Lassa-VSV successfully targets and kills glioblastoma cells that are transplanted into the brain, both after an intratumoral virus injection, and after intravenous inoculation. We use both glioma cell lines and primary human gliomas transplanted into immunodeficient mice. We also test syngeneic mouse glioma implanted into immunocompetent mouse host brains. Tumors are detected by expression of a red fluorescent reporter and virally infected cells are detected by expression of a reporter gene coding for green fluorescent protein. In the second Aim, we address the hypothesis that the mechanism behind the safety and selectivity of Lassa-VSV in the brain is that the virus either does not bind to receptors on neurons or normal glia, or is not internalized, whereas binding and internalization in glioma is robust. The lack of virus infection of neurons is studied by blocking or enhancing various steps in the infectious pathway coupled with reverse transcriptase quantitative PCR, and corroborated with electron microscopy, and in additional species and in human brain slices. A key hypothesis we test in Aim 3 is that Lassa-VSV initiates an attack by the systemic immune system, particularly by CD8+ T cells, on the glioma that continues even after the virus is eliminated, thereby preventing the recurrence of tumor. This is tested by infection of glioma in the brain; after the virus is eliminated, we examin the potential of newly implanted glioma to grow in the presence of the enhanced immune response. Immune targeting is complemented with adoptive transfer, CD8-T cell elimination, and immunocytochemistry to detect immune cells recruited to the infected tumor. Lassa-VSV is remarkable in that it can completely kill glioma with no detectable adverse side effects in the brain or elsewhere. If our experiments are successful, we think this virus would be a top priority candidate for clinical trials.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ANTHONY N VAN DEN POL其他文献
ANTHONY N VAN DEN POL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ANTHONY N VAN DEN POL', 18)}}的其他基金
Zona incerta GABA neurons modulate energy homeostasis
未定带 GABA 神经元调节能量稳态
- 批准号:
9564671 - 财政年份:2017
- 资助金额:
$ 35.32万 - 项目类别:
Zona incerta GABA neurons modulate energy homeostasis
未定带 GABA 神经元调节能量稳态
- 批准号:
9426268 - 财政年份:2017
- 资助金额:
$ 35.32万 - 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
- 批准号:
8888338 - 财政年份:2015
- 资助金额:
$ 35.32万 - 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
- 批准号:
9015803 - 财政年份:2015
- 资助金额:
$ 35.32万 - 项目类别:
Lassa-VSV targets and kills glioma, and is not neurotoxic
Lassa-VSV 靶向并杀死神经胶质瘤,并且不具有神经毒性
- 批准号:
9043833 - 财政年份:2015
- 资助金额:
$ 35.32万 - 项目类别:
Dopamine Excites Orexigenic AgRP/NPY Neurons, but Inhibits Anorexic POMC Neurons
多巴胺兴奋促食欲 AgRP/NPY 神经元,但抑制厌食 POMC 神经元
- 批准号:
9213370 - 财政年份:2015
- 资助金额:
$ 35.32万 - 项目类别:
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
水疱性口炎VSVrp30选择性破坏人类转移性黑色素瘤
- 批准号:
8826056 - 财政年份:2012
- 资助金额:
$ 35.32万 - 项目类别:
Vesicular stomatitis VSVrp30 selectively destroys human metastatic melanoma
水疱性口炎VSVrp30选择性破坏人类转移性黑色素瘤
- 批准号:
9027807 - 财政年份:2012
- 资助金额:
$ 35.32万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 35.32万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 35.32万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 35.32万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 35.32万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 35.32万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 35.32万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 35.32万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 35.32万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 35.32万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 35.32万 - 项目类别:














{{item.name}}会员




